ARCT
Price
$15.49
Change
+$0.65 (+4.38%)
Updated
Dec 20, 04:59 PM (EDT)
71 days until earnings call
PGEN
Price
$0.76
Change
+$0.03 (+4.11%)
Updated
Dec 20, 04:59 PM (EDT)
66 days until earnings call
Ad is loading...

ARCT vs PGEN

Header iconARCT vs PGEN Comparison
Open Charts ARCT vs PGENBanner chart's image
Arcturus Therapeutics Holdings
Price$15.49
Change+$0.65 (+4.38%)
Volume$14.94K
CapitalizationN/A
Precigen
Price$0.76
Change+$0.03 (+4.11%)
Volume$12.59K
CapitalizationN/A
ARCT vs PGEN Comparison Chart
Loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ARCT vs. PGEN commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARCT is a Hold and PGEN is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (ARCT: $15.48 vs. PGEN: $0.76)
Brand notoriety: ARCT and PGEN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARCT: 195% vs. PGEN: 197%
Market capitalization -- ARCT: $419.31M vs. PGEN: $223.34M
ARCT [@Biotechnology] is valued at $419.31M. PGEN’s [@Biotechnology] market capitalization is $223.34M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARCT’s FA Score shows that 0 FA rating(s) are green whilePGEN’s FA Score has 0 green FA rating(s).

  • ARCT’s FA Score: 0 green, 5 red.
  • PGEN’s FA Score: 0 green, 5 red.
According to our system of comparison, ARCT is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARCT’s TA Score shows that 4 TA indicator(s) are bullish while PGEN’s TA Score has 3 bullish TA indicator(s).

  • ARCT’s TA Score: 4 bullish, 4 bearish.
  • PGEN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, ARCT is a better buy in the short-term than PGEN.

Price Growth

ARCT (@Biotechnology) experienced а -10.05% price change this week, while PGEN (@Biotechnology) price change was +12.93% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

ARCT is expected to report earnings on Mar 03, 2025.

PGEN is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ARCT($419M) has a higher market cap than PGEN($223M). PGEN YTD gains are higher at: -43.090 vs. ARCT (-50.904). ARCT has higher annual earnings (EBITDA): -25.93M vs. PGEN (-136.11M). ARCT has more cash in the bank: 237M vs. PGEN (28.6M). PGEN has less debt than ARCT: PGEN (5.75M) vs ARCT (29.4M). ARCT has higher revenues than PGEN: ARCT (142M) vs PGEN (3.96M).
ARCTPGENARCT / PGEN
Capitalization419M223M188%
EBITDA-25.93M-136.11M19%
Gain YTD-50.904-43.090118%
P/E RatioN/AN/A-
Revenue142M3.96M3,583%
Total Cash237M28.6M829%
Total Debt29.4M5.75M511%
FUNDAMENTALS RATINGS
ARCT vs PGEN: Fundamental Ratings
ARCT
PGEN
OUTLOOK RATING
1..100
6250
VALUATION
overvalued / fair valued / undervalued
1..100
48
Fair valued
54
Fair valued
PROFIT vs RISK RATING
1..100
93100
SMR RATING
1..100
9499
PRICE GROWTH RATING
1..100
8687
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/a44

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ARCT's Valuation (48) in the Pharmaceuticals Major industry is in the same range as PGEN (54) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's Profit vs Risk Rating (93) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's SMR Rating (94) in the Pharmaceuticals Major industry is in the same range as PGEN (99) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's Price Growth Rating (86) in the Pharmaceuticals Major industry is in the same range as PGEN (87) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

ARCT's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as PGEN (100) in the null industry. This means that ARCT’s stock grew similarly to PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARCTPGEN
RSI
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
88%
Momentum
ODDS (%)
Bearish Trend 3 days ago
83%
Bearish Trend 3 days ago
90%
MACD
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
86%
Bullish Trend 3 days ago
84%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 3 days ago
82%
Bullish Trend 3 days ago
83%
Declines
ODDS (%)
Bearish Trend 5 days ago
84%
Bearish Trend 7 days ago
86%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
87%
N/A
Aroon
ODDS (%)
Bearish Trend 3 days ago
85%
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
ARCT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
RYMKX56.760.78
+1.39%
Rydex Russell 2000 1.5x Strategy H
MDMIX28.450.33
+1.17%
Madison Dividend Income I
IGHAX11.690.09
+0.78%
Voya Global High Dividend Low Vol Port A
FCVIX20.500.15
+0.74%
Fidelity Advisor Small Cap Value I
BIFRX19.13-0.08
-0.42%
BlackRock International R

ARCT and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARCT has been loosely correlated with BMEA. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if ARCT jumps, then BMEA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARCT
1D Price
Change %
ARCT100%
+4.31%
BMEA - ARCT
52%
Loosely correlated
+3.68%
AXON - ARCT
49%
Loosely correlated
+2.60%
ABCL - ARCT
48%
Loosely correlated
+5.17%
PGEN - ARCT
45%
Loosely correlated
+5.07%
BEAM - ARCT
44%
Loosely correlated
+8.04%
More

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with CRSP. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
+5.07%
CRSP - PGEN
53%
Loosely correlated
+0.83%
NTLA - PGEN
51%
Loosely correlated
+0.83%
RCKT - PGEN
50%
Loosely correlated
+1.85%
BEAM - PGEN
50%
Loosely correlated
+8.04%
NKTX - PGEN
50%
Loosely correlated
+7.73%
More